Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
256 questions in 49 reviews · Haematology
current versionsNo studies 256 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Recombinant human soluble thrombomodulin vs heparin Shock · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | NR | No studies |
Dermatan vs heparin Resolution of respiratory failure ‐ not measured · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | NR | No studies |
Dermatan vs heparin Renal failure · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | NR | No studies |
Dermatan vs heparin Shock · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | NR | No studies |
Human activated protein C vs heparin Resolution of respiratory failure · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | NR | No studies |
Human activated protein C vs heparin Renal failure · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | NR | No studies |
Human activated protein C vs heparin Shock · DIC Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Heparin vs no treatment Quality of life · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases… Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Low molecular weight heparin vs placebo or no treatment Overall survival · People undergoing stem cell transplant with malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Low molecular weight heparin vs placebo or no treatment All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Low molecular weight heparin vs placebo or no treatment Mortality attributable to hepatic veno‐occlusive disease · People undergoing stem cell transplant with malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Low molecular weight heparin vs placebo or no treatment Quality of life · People undergoing stem cell transplant with malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Defibrotide vs no treatment Quality of life · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic… Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Glutamine vs placebo Overall survival · People undergoing stem cell transplant with haematological malignancies Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Glutamine vs placebo Quality of life · People undergoing stem cell transplant with haematological malignancies Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Fresh frozen plasma vs no treatment Overall survival · People undergoing stem cell transplants with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Fresh frozen plasma vs no treatment All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplants with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Fresh frozen plasma vs no treatment Mortality attributable to hepatic veno‐occlusive disease · People undergoing stem cell transplants with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Fresh frozen plasma vs no treatment Quality of life · People undergoing stem cell transplants with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Fresh frozen plasma vs no treatment Frequency of adverse events · People undergoing stem cell transplants with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Antithrombin III plus heparin vs heparin alone Overall survival · People undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Antithrombin III plus heparin vs heparin alone All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Antithrombin III plus heparin vs heparin alone Quality of life · People undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Heparin vs low molecular weight heparin Overall survival · Patients undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Heparin vs low molecular weight heparin All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Heparin vs low molecular weight heparin Quality of life · Patients undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Ursodeoxycholic acid vs placebo or no treatment Quality of life · People undergoing stem cell transplant with a variety of malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Heparin vs prostaglandin E1 Overall survival · Patients undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Heparin vs prostaglandin E1 All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Heparin vs prostaglandin E1 Quality of life · Patients undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Low molecular weight heparin vs prostaglandin E1 Overall survival · People undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Low molecular weight heparin vs prostaglandin E1 All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Low molecular weight heparin vs prostaglandin E1 Quality of life · People undergoing stem cell transplant with malignant and non‐malignant diseases Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life · individuals with HL Positron emission tomography‐adapted therapy for first‐line treatment in individuals with Hodgkin lymphoma (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Treatment related mortality · individuals with HL Positron emission tomography‐adapted therapy for first‐line treatment in individuals with Hodgkin lymphoma (2015) · Cochrane | no estimate extracted | NR | No studies |
Plerixafor vs placebo Quality of life · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple… Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation… (2015) · Cochrane | no estimate extracted | NR | No studies |
Plerixafor vs placebo Progression‐free survival · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple… Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation… (2015) · Cochrane | no estimate extracted | NR | No studies |
Plerixafor vs placebo Time to engraftment · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple… Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation… (2015) · Cochrane | no estimate extracted | NR | No studies |
Plerixafor vs placebo Number of transplanted participants · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple… Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation… (2015) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000) Quality of life ‐ not reported · People with a haematological disorder Comparison of different platelet count thresholds to guide administration of prophylactic platelet… (2015) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule Quality of life ‐ not reported · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic platelet transfusions with high‐dose schedule vs standard‐dose schedule Quality of life ‐ not reported · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic platelet transfusions with low‐dose schedule vs prophylactic platelet transfusions with standard‐dose schedule Quality of life ‐ not reported · People with a haematological disorder Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mortality secondary to bleeding/infection/transfusion reactions or iron overload ‐ not reported · patients with myelodysplastic syndrome Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia,… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life ‐ not reported · patients with myelodysplastic syndrome Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia,… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Frequency and length of hospital admissions ‐ not reported · patients with myelodysplastic syndrome Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia,… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Serious infections (requiring admission to hospital) ‐ not reported · patients with myelodysplastic syndrome Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia,… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Serious bleeding (e.g. WHO/CTCAE grade 3 (or equivalent) or above ) ‐ not reported · patients with myelodysplastic syndrome Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia,… (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Treatment‐related mortality · Participants with PCNSL The role of additional radiotherapy for primary central nervous system lymphoma (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life · Participants with PCNSL The role of additional radiotherapy for primary central nervous system lymphoma (2014) · Cochrane | no estimate extracted | NR | No studies |